Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Moonlake Immunotherapeutics AG
Industry Sector: HealthTechnology
CEO: Jorge Santos da Silva, PhD
Number Of Employees: 100
Enterprise Value: $2,965,791,682
PE Ratio: -20.31
Exchange/Ticker 1: NASDAQ:MLTX
Exchange/Ticker 2: N/A
Latest Market Cap: $2,429,422,848
See Emerging Company Profile .
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Dec 11, 2023
Product Development
Building on dermatology’s recent success
Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology
BioCentury | Nov 6, 2023
Deals
Nov. 6 Quick Takes: BMS buying Orum’s protein degrader
Plus: Ventyx terminates VTX958 in plaque psoriasis, psoriatic arthritis and updates from Celldex, MoonLake and ProfoundBio
BioCentury | Oct 17, 2023
Deals
Oct. 16 Quick Takes: Novo turns to Singapore’s KBP for hypertension asset
Plus: Gout company Atom raises $83M and updates from AbbVie, BeiGene, Amgen, Daiichi and MoonLake
BioCentury | Oct 12, 2023
Product Development
MC2's Hsp90 inhibitor shows signs of efficacy in hidradenitis suppurativa
Readout sets up ‘first-in-class’ therapy for Phase IIb study in increasingly competitive inflammatory disease
BioCentury | Jul 15, 2023
Finance
Out of the abyss: 3Q23 market preview
Biotech investors see the worst fading into the rearview mirror,
BioCentury | Jun 29, 2023
Finance
June 28 Quick Takes: MoonLake’s $400M follow-on among several cash raises
Plus: Axsome taps investors for $225M, and updates from Immutep, K36, Pfizer, Zai Lab and more
BioCentury | Jun 26, 2023
Data Byte
Data comp: MoonLake sets efficacy bar in hidradenitis suppurativa
Sonelokimab shows 29% improvement vs. placebo on HiSCR75 endpoint, besting two other programs
Items per page:
1 - 10 of 19